Our work was in line with a study by Alsina et al., showing that inhibition of TGF-β can block tumor growth in orthotopic preclinical models of ovarian cancer (PDX) (Alsina-Sanchis et al., 2016). This evidence concerns the gene TGFB1 and ovarian cancer.